Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
13:29:51 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



Q:AGRX - AGILE THERAPEUTICS INC - https://ir.agiletherapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
AGRX - Qnot subscribed0.4028.111350.425  0.43  0.3956.97  0.2015:49:35Mar 2815 min RT 2¢

Recent Trades - Last 10 of 35
Time ETExPriceChangeVolume
15:49:35Q0.40 7
15:49:31Q0.414850.014851
15:49:31Q0.417820.017824
14:59:40Q0.40 4,500
14:59:26Q0.40 2,500
14:59:25Q0.417850.017851,000
14:42:17Q0.410.01157
13:55:10Q0.417850.017851
13:06:42Q0.40 300
12:50:43Q0.421420.021423,000

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-03-28 08:05U:AGRXNews ReleaseAgile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
2024-03-25 16:30U:AGRXNews ReleaseAgile Therapeutics Announces Delisting from Nasdaq
2024-03-21 06:35U:AGRXNews ReleaseCorrection - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024
2024-03-20 08:15U:AGRXNews ReleaseAgile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024
2024-03-13 07:31U:AGRXNews ReleaseAgile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution
2024-02-22 09:01U:AGRXNews ReleaseAgile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
2024-02-15 16:30U:AGRXNews ReleaseAgile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders ¢ € ™ Equity Continued Listing Requirement & Provides Performance Update
2024-01-23 09:29U:AGRXNews ReleaseThe Biden-Harris Administration Announces New Guidance to Enable Expanded Access to All FDA-Approved Contraceptives Without Cost
2023-12-12 08:01U:AGRXNews ReleaseAgile Therapeutics Provides Update on Actions Being Taken to Strengthen the Affordable Care Act ¢ € ™s No-Cost Contraceptive Coverage Requirement
2023-11-22 09:02U:AGRXNews ReleaseAgile Therapeutics Posts Growth In Third Quarter Results, Reiterates Confidence In Target of $25M Net Revenue, Positive Cash Flow In 2024
2023-11-09 08:05U:AGRXNews ReleaseAgile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
2023-10-26 08:05U:AGRXNews ReleaseAgile Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on Thursday, November 9, 2023
2023-10-04 16:30U:AGRXNews ReleaseAgile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
2023-09-28 09:02U:AGRXNews ReleaseAgile Therapeutics (NASDAQ: AGRX) Upgraded To ¢ € œBuy ¢ €  Rating By Analysts At Maxim Group
2023-09-05 08:06U:AGRXNews ReleaseAgile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
2023-08-17 09:02U:AGRXNews ReleaseAgile Says It's On Track To Hit $25-$30 Million Net Annual Revenue After A Strong Performance In Its Second Quarter
2023-08-09 08:05U:AGRXNews ReleaseAgile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
2023-07-26 08:30U:AGRXNews ReleaseAgile Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Plan Updates on Wednesday, August 9, 2023
2023-07-19 09:01U:AGRXNews ReleaseThis Reproductive Health Company's Weekly Contraceptive Patch Can Reach Millions of Women Thanks to a Partnership With Afaxys
2023-07-18 09:02U:AGRXNews ReleaseAgile Therapeutics Partners With Telehealth Platforms To Expand Access To Weekly Birth Control Patch To Millions Of Women